Payment overview · 2025
General Payments
$1,691.10
90 reported records · 17 companies
Healthcare provider profile · identity verified
Robert Francis Bundy, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · MOORESVILLE, NC · NPI 1518946458
Verified facts
What the public records show
CMS Open Payments records show Robert Francis Bundy, M.D. received $1,691.10 in general payments during 2025 across 90 reported records.
Novo Nordisk Inc accounted for 20.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Ozempic, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 167 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 207 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Trelegy Ellipta by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 166 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $351.54 | 20.8% | 22 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $325.54 | 19.2% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $243.16 | 14.4% | 14 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $224.65 | 13.3% | 15 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $181.85 | 10.8% | 12 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $92.68 | 5.5% | 6 | 2025 |
| Verity Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $39.80 | 2.4% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $39.28 | 2.3% | 4 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $31.89 | 1.9% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $29.21 | 1.7% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $23.86 | 1.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $21.53 | 1.3% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $18.60 | 1.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.81 | 1.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.54 | 1.0% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $17.26 | 1.0% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $14.90 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,691.10 | 90 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $325.54 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $291.80 | 18 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $291.80 | 18 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $243.16 | 14 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $181.85 | 12 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $156.42 | 9 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $155.00 | 9 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $108.67 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $92.68 | 6 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $86.74 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $50.11 | 5 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $39.28 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $32.59 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $31.89 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $29.21 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $23.86 | 1 | 2025 |
Source payment records
|
|||||
| Tlando Normalized: tlando |
Drug | Verity Pharmaceuticals Inc. | $23.81 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $21.53 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $21.53 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $18.60 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $17.81 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.54 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $17.26 | 1 | 2025 |
Source payment records
|
|||||
| Trelstar Normalized: trelstar |
Drug | Verity Pharmaceuticals Inc. | $15.99 | 1 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $14.90 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 166 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 207 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 125 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 105 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
31 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
40 | 14 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
71 | 20 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
167 | 50 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
207 | 52 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
105 | 25 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
125 | 33 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
166 | 38 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 772 | 235 |
| Atorvastatin Calcium | Atorvastatin Calcium | 752 | 205 |
| Levothyroxine Sodium | Levothyroxine Sodium | 713 | 176 |
| Amlodipine Besylate | Amlodipine Besylate | 701 | 197 |
| Losartan Potassium | Losartan Potassium | 545 | 148 |
| Pantoprazole Sodium | Pantoprazole Sodium | 391 | 101 |
| Metformin Hcl | Metformin Hcl | 367 | 109 |
| Ezetimibe | Ezetimibe | 357 | 108 |
| Lisinopril | Lisinopril | 340 | 82 |
| Alendronate Sodium | Alendronate Sodium | 328 | 90 |
| Omeprazole | Omeprazole | 256 | 83 |
| Famotidine | Famotidine | 255 | 68 |
| Escitalopram Oxalate | Escitalopram Oxalate | 237 | 52 |
| Alprazolam | Alprazolam | 235 | 60 |
| Jardiance | Empagliflozin | 207 | 52 |
| Pravastatin Sodium | Pravastatin Sodium | 202 | 57 |
| Trazodone Hcl | Trazodone Hcl | 195 | 57 |
| Sertraline Hcl | Sertraline Hcl | 187 | 41 |
| Metoprolol Succinate | Metoprolol Succinate | 179 | 63 |
| Memantine Hcl | Memantine Hcl | 177 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 170 | 57 |
| Metformin Hcl Er | Metformin Hcl | 168 | 50 |
| Farxiga | Dapagliflozin Propanediol | 167 | 50 |
| Eliquis | Apixaban | 166 | 38 |
| Prednisone | Prednisone | 165 | 128 |
| Hydrochlorothiazide | Hydrochlorothiazide | 164 | 57 |
| Gabapentin | Gabapentin | 139 | 51 |
| Mirtazapine | Mirtazapine | 127 | 26 |
| Ozempic | Semaglutide | 125 | 33 |
| Simvastatin | Simvastatin | 114 | 30 |
| Tramadol Hcl | Tramadol Hcl | 112 | 46 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 105 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 103 | 40 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 102 | 53 |
| Donepezil Hcl | Donepezil Hcl | 100 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 99 | 31 |
| Carvedilol | Carvedilol | 95 | 24 |
| Mounjaro | Tirzepatide | 95 | 19 |
| Telmisartan | Telmisartan | 93 | 32 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 90 | 28 |
| Repatha Sureclick | Evolocumab | 89 | 23 |
| Furosemide | Furosemide | 83 | 28 |
| Allopurinol | Allopurinol | 81 | 25 |
| Bupropion Xl | Bupropion Hcl | 80 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 75 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 74 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 73 | 18 |
| Meloxicam | Meloxicam | 71 | 43 |
| Myrbetriq | Mirabegron | 71 | 20 |
| Montelukast Sodium | Montelukast Sodium | 69 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 67 | 22 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 62 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 60 | 54 |
| Lorazepam | Lorazepam | 58 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 57 | 53 |
| Glimepiride | Glimepiride | 57 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 57 | 18 |
| Finasteride | Finasteride | 56 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 54 | 15 |
| Clonazepam | Clonazepam | 52 | 14 |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 49 | 16 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 48 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 46 | 41 |
| Cefdinir | Cefdinir | 45 | 43 |
| Potassium Chloride | Potassium Chloride | 44 | 25 |
| Quetiapine Fumarate | Quetiapine Fumarate | 43 | 15 |
| Gemtesa | Vibegron | 42 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 41 | 21 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 41 | 11 |
| Xarelto | Rivaroxaban | 41 | suppressed |
| Glipizide | Glipizide | 40 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 40 | 11 |
| Synthroid | Levothyroxine Sodium | 40 | 14 |
| Buspirone Hcl | Buspirone Hcl | 39 | 11 |
| Spironolactone | Spironolactone | 39 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 38 | 17 |
| Diltiazem 24hr Er | Diltiazem Hcl | 38 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 38 | suppressed |
| Amoxicillin | Amoxicillin | 37 | 30 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 36 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 36 | suppressed |
| Januvia | Sitagliptin Phosphate | 36 | suppressed |
| Olanzapine | Olanzapine | 36 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 36 | 19 |
| Atenolol | Atenolol | 34 | suppressed |
| Metronidazole | Metronidazole | 34 | 32 |
| Fluoxetine Hcl | Fluoxetine Hcl | 33 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 33 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 32 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 32 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 32 | suppressed |
| Valsartan | Valsartan | 32 | suppressed |
| Linzess | Linaclotide | 31 | 13 |
| Azithromycin | Azithromycin | 30 | 21 |
| Diazepam | Diazepam | 30 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 30 | suppressed |
| Nystatin | Nystatin | 29 | 16 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 28 | 22 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 21 |
| Warfarin Sodium | Warfarin Sodium | 28 | suppressed |
| Lovastatin | Lovastatin | 27 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 27 | suppressed |
| Pregabalin | Pregabalin | 27 | 11 |
| Sucralfate | Sucralfate | 27 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 26 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 26 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 26 | suppressed |
| Timolol Maleate | Timolol Maleate | 26 | suppressed |
| Fluconazole | Fluconazole | 25 | 19 |
| Labetalol Hcl | Labetalol Hcl | 25 | suppressed |
| Risperidone | Risperidone | 25 | suppressed |
| Vascepa | Icosapent Ethyl | 25 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Estradiol | Estradiol | 24 | 13 |
| Celecoxib | Celecoxib | 23 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | 11 |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Sutab | Sod Sulf/Pot Chloride/Mag Sulf | 23 | 23 |
| Trulicity | Dulaglutide | 23 | suppressed |
| Eszopiclone | Eszopiclone | 22 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Silodosin | Silodosin | 21 | suppressed |
| Dutasteride | Dutasteride | 20 | suppressed |
| Methocarbamol | Methocarbamol | 20 | 17 |
| Oxycodone Hcl | Oxycodone Hcl | 20 | suppressed |
| Primidone | Primidone | 20 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 20 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Calcitriol | Calcitriol | 19 | suppressed |
| Colchicine | Colchicine | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 19 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 19 | suppressed |
| Belsomra | Suvorexant | 18 | suppressed |
| Cephalexin | Cephalexin | 18 | 18 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 18 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 18 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Latanoprost | Latanoprost | 17 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 16 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Loperamide | Loperamide Hcl | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Praluent Pen | Alirocumab | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 14 |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Repatha Syringe | Evolocumab | 14 | suppressed |
| Sotalol | Sotalol Hcl | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Creon | Lipase/Protease/Amylase | 13 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 13 | suppressed |
| Livalo | Pitavastatin Calcium | 13 | suppressed |
| Novofine 32 | Pen Needle, Diabetic | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Vraylar | Cariprazine Hcl | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,691.10 · 90 records | Novo Nordisk Inc | AIRSUPRA, Cologuard Collection Kit, ELIQUIS, EVENITY, INSPIRE, JARDIANCE, Kerendia, LEQVIO, NURTEC ODT, Ozempic, PROLIA, QULIPTA, REXULTI, Rybelsus, TRELEGY ELLIPTA, Tlando, Trelstar, UBRELVY, UNITHROID, VOQUEZNA, VRAYLAR, Veozah, Wegovy, XIFAXAN, ZAVZPRET | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error